Thymosin alpha-1: immune effects, no proven aging benefit

Evidence as of September 2026.

• Shown: thymosin alpha-1 can change some immune measurements and has a registered prescription use for specified hepatitis treatment in Singapore. [2] [6]

• Not shown: a clear survival benefit in the larger sepsis trial, or prevention of serious illness through routine use for healthy aging. [4]

• Would change the assessment: completed trials showing fewer confirmed infections or serious complications, with adequate safety follow-up.

The larger sepsis trial changed the picture

An encouraging early survival result was not confirmed by the larger, more rigorously blinded trial. Sepsis is a life-threatening response to infection that damages organs; its findings should not be treated as results in healthy older people.

ETASS’s result depended on the statistical method: the simple comparison of death proportions missed the usual significance threshold, while an analysis including timing narrowly crossed it. Treating clinicians knew the assignments, and baseline differences added uncertainty. [3]

TESTS concealed treatment from patients and clinicians at 22 Chinese centers. The corrected hazard ratio was 0.97, with a 95% confidence interval of 0.76–1.24. A value of 1 means no difference; the uncertainty range included both benefit and harm. The result does not exclude every small effect, but it does not show a clear survival advantage. [4] [5]

The May 2025 correction replaced outdated survival and immune-cell entries. It was not a retraction and did not turn the study into a positive trial. TESTS received public research funding and SciClone support; author commercial relationships were disclosed, and the paper states that funders did not direct its conduct or interpretation. [4] [5]

What does “changing immunity” actually mean?

Thymosin alpha-1 alters parts of the immune response; “immune booster” is too vague to describe its value. The immune system must recognize threats, respond and then control inflammation. A larger response is not always a better one. [1]

The peptide contains 28 amino acids, and its synthetic form is called thymalfasin. It is different from thymosin beta-4, TB-500 and thymus extracts. Its association with the thymus does not demonstrate that injections regenerate the organ. Finished medicines and bulk ingredients also differ in formulation and manufacturing control. [1] [7]

Do vaccine studies show fewer infections?

The cited studies provide immune-response signals, not a dependable prevention result for healthy older adults.

The influenza study analyzed samples from 85 men and found no between-group difference in those aged 65–76. Its antibody-binding test did not directly show protection from infection. No toxicity was observed, but FDA’s later assessment found the vaccine evidence inconsistent and insufficient for a dependable safety assessment of that use. [1] [6]

The dialysis report lacked placebo, vaccinations occurred at different times, and the authors explicitly described unfinished follow-up. It acknowledged SciClone funding and consulting payments while also declaring no known competing interests. Both statements matter. The death counts cannot establish COVID-19 prevention or generalize to healthy older adults. [11]

The Houston Methodist phase 1 study, NCT06821100, tests thymalfasin before COVID-19 boosters. Its July 16, 2026 registry entry describes random assignment without concealment, safety as the main goal, and antibody and T-cell measurements. A favorable marker alone would still leave the clinical prevention question open. [8] [12]

What are the risks?

Many studies reported few treatment-attributed problems, commonly injection-site irritation, redness or discomfort. That is useful experience, but it does not settle long-term use in healthy people. FDA also highlights impurities, peptide clumping and unwanted immune responses for proposed compounded preparations. [1] [7]

After a seven-day TESTS course, overall adverse-event frequencies were similar over 90 days. Age-subgroup analyses raised a possible harm signal below age 60; an exploratory adjustment weakened it. The older subgroup did not have a confirmed survival benefit. These findings need confirmation and do not establish safety over years. [4]

Singapore’s product information prohibits use with allergy to the product. It also restricts use when immunity is deliberately suppressed, such as after organ transplantation, unless potential benefits clearly outweigh risks. Altering immunity may conflict with the purpose of another treatment. [2]

Where is it approved, and what did the US vote mean?

Singapore’s official formulary registers Zadaxin for specified chronic hepatitis B and C uses and names SciClone as license holder. It does not list healthy aging, establish current stock or indicate which hepatitis treatment is preferred today. [2]

FDA’s November 2024 assessment stated that neither the free base nor acetate was an ingredient in an FDA-approved drug. On December 4, 2024, its advisory committee voted 17–4 against adding each form to the 503A compounding list. Those were advisory ingredient votes, not finished-medicine approval decisions. [1] [10]

What should we watch next?

The useful next step is to see whether a defined immune change helps people avoid illness.

• Older-adult vaccination: results and harms from the Houston Methodist study described in July 2026. [12]

• Dialysis pilot: complete follow-up and the planned efficacy analysis beyond the 2023 preliminary report. [11]

• Sepsis: independent confirmation of any proposed responsive subgroup following TESTS, rather than selecting a favorable subgroup after a negative overall result. [4]

How Healthy Longevity Clinic experts evaluate the evidence

Healthy Longevity Clinic judges an immune-aging intervention by whether people have fewer infections, less severe illness or better recovery. A change in an immune-cell count may help explain a mechanism, but it does not substitute for those outcomes. This is the distinction to keep in mind when reading the vaccine studies.

Thymosin alpha-1 has real clinical research, and its results differ by setting. The large sepsis trial's lack of a clear survival benefit matters; so does the fact that sepsis, hepatitis and prevention in generally healthy older adults are different questions. Neither an overseas registration nor a laboratory response settles the preventive-use claim.

For today's reader, the useful discussion is about vaccination needs, established preventive care and the cause of recurrent or unusual infections. An isolated immune marker should not become the goal of care. Direct evidence of fewer serious infections with acceptable harms would make the preventive treatment case more convincing. [9]

Three questions for a treatment discussion

1. Is the goal hepatitis treatment, a vaccine response or prevention in a healthy person?

2. Did the study show fewer illnesses, or only a changed antibody or cell measurement?

3. Could altering immunity conflict with another treatment, and what follow-up supports the proposed duration?

Frequently asked questions

Does thymosin alpha-1 improve immunity with age?

Some immune measurements have improved in selected studies. A reliable reduction in serious infections or a broader healthy-aging benefit in generally healthy older adults has not been established here. [1] [6]

Is thymosin alpha-1 approved in the US?

The FDA assessment cited here states that the reviewed forms are not ingredients in an approved drug. Singapore’s Zadaxin registration is a separate, jurisdiction-specific status. [1] [2]

Did the large sepsis trial save lives?

It did not show a clear survival benefit: corrected 28-day mortality was 23.4% versus 24.1% with placebo. [4] [5]